Eisai Overview
- Year Founded
-
1941
- Status
-
Public
- Employees
-
10,543
- Stock Symbol
-
4523
- Investments
-
39
- Share Price
-
$33.30
- (As of Thursday Closing)
Eisai General Information
Description
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
Contact Information
Website
www.eisai.comCorporate Office
- 4-6-10 Koishikawa
- Tokyo, Bunkyo-ku 112-8088
- Japan
Corporate Office
- 4-6-10 Koishikawa
- Tokyo, Bunkyo-ku 112-8088
- Japan
Eisai Stock Performance
As of 19-Nov-2026, Eisai’s stock price is $33.30. Its current market cap is $9.4B with 282M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $33.30 | $32.85 | $22.80 - $33.64 | $9.4B | 282M | 1.26M | $0.99 |
Eisai Financials Summary
As of 30-Sep-2026, Eisai has a trailing 12-month revenue of $5.69B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 8,488,036 | 8,192,563 | 7,486,902 | 11,130,507 |
| Revenue | 5,688,806 | 5,476,055 | 5,176,457 | 5,133,586 |
| EBITDA | 570,904 | 555,237 | 618,257 | 642,294 |
| Net Income | 278,688 | 255,817 | 304,482 | 293,495 |
| Total Assets | 9,685,184 | 9,065,002 | 9,265,739 | 9,209,112 |
| Total Debt | 1,619,549 | 1,164,039 | 1,253,141 | 1,053,221 |
Eisai Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eisai Comparisons
Industry
Financing
Details
Eisai Competitors (23)
One of Eisai’s 23 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| GSK | Corporation | London, United Kingdom | ||||
| China Resources Pharmaceutical Group | Corporation | Hong Kong, Hong Kong | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Roche | Corporation | Basel, Switzerland |
Eisai Patents
Eisai Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026197354-A1 | Anti-transferrin receptor antibody | Pending | 21-Mar-2025 | ||
| US-20260297208-A1 | Bispecific antibody | Pending | 21-Mar-2025 | ||
| WO-2026197356-A1 | Bispecific antibody | Pending | 21-Mar-2025 | ||
| WO-2026169921-A1 | Combination therapies comprising eribulin-based antibody-drug conjugates | Pending | 06-Feb-2025 | ||
| WO-2026152108-A1 | Systems and methods for predicting cognitive impairment progression in individuals with preclinical alzheimer's disease | Pending | 13-Jan-2025 | G16B40/20 |
Eisai Signals
Eisai Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eisai Investments & Acquisitions (39)
Eisai’s most recent deal was a Later Stage VC with Beren Therapeutics for . The deal was made on 10-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Beren Therapeutics | 10-Jun-2026 | Later Stage VC | Drug Discovery | ||
| VIVACTA Biotechnology | 26-Jan-2026 | Early Stage VC | Drug Discovery | ||
| Seed Therapeutics | 01-Aug-2025 | Later Stage VC | Drug Discovery | ||
| EcoNaviSta | 07-May-2025 | Merger/Acquisition | Medical Records Systems | ||
| Periotherapia | 31-Jan-2025 | Later Stage VC | Drug Discovery |
Eisai ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
24.72 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Eisai Exits (9)
Eisai’s most recent exit was on 09-Jan-2025 from Numab Therapeutics. The exit was categorized as with 10 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Numab Therapeutics | 09-Jan-2025 | Completed |
|
||
| PRISM BioLab | 24-Jan-2024 | Completed |
|
||
| Allm | 05-Apr-2021 | Completed |
|
||
| Caraway Therapeutics | 26-Nov-2018 | Completed |
|
||
| Voluntis | 01-Apr-2018 | Later Stage VC | Completed |
|
Eisai Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Eisai Ventures | Tokyo, Japan | 2019 | |
| Eisai Innovation | Cambridge, MA | 2019 |
Eisai FAQs
-
When was Eisai founded?
Eisai was founded in 1941.
-
Where is Eisai headquartered?
Eisai is headquartered in Tokyo, Japan.
-
What is the size of Eisai?
Eisai has 10,543 total employees.
-
What industry is Eisai in?
Eisai’s primary industry is Pharmaceuticals.
-
Is Eisai a private or public company?
Eisai is a Public company.
-
What is Eisai’s stock symbol?
The ticker symbol for Eisai is 4523.
-
What is the current stock price of Eisai?
As of 19-Nov-2026 the stock price of Eisai is $33.30.
-
What is the current market cap of Eisai?
The current market capitalization of Eisai is $9.4B.
-
What is Eisai’s current revenue?
The trailing twelve month revenue for Eisai is $5.69B.
-
Who are Eisai’s competitors?
Evonile Pharma, GSK, China Resources Pharmaceutical Group, Novartis, and Roche are some of the 23 competitors of Eisai.
-
What is Eisai’s annual earnings per share (EPS)?
Eisai’s EPS for 12 months was $0.99.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process